No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]
Hamed K, Wiktorowicz T, Assadi Gehr M. Infect Drug Resist. 2020;13:3209— 3215.
The authors have advised that the Funding statement was missing on page 3214 of the published paper. This error was introduced by the Editorial staff during the publication process. The funding statement should read as follows:
The TARGET and ERADICATE trials were supported in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600002C; and in part by Basilea Pharmaceutica International Ltd., Basel, Switzerland. BPR-PIP-002 trial was funded by Basilea Pharmaceutica International Ltd., Basel, Switzerland.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]